Potvin B, C, or D? [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2011-10-28 00:52 (5342 d 03:23 ago) – Posting: # 7557
Views: 21,854

Dear D. Labes!

❝ ❝ Why don't we discuss method C in stead where the authors make a clear discussion between alpha1 and alpha2; it is for many practical purposes performing just like method B anyway, at least under the conditions tested by Potvin :-D.


❝ I can not see the 'clear discussion' for alpha1 and alpha2 in the Potvin et al. paper.


Me not either. I’ve heard that regulators read this forum; so if they have no access to the paper here’s a snippet from its Section 5 (Discussion and Recommendations)

The goal of our group was to validate at least one method for two-stage designs that could be used for BE studies. Methods B and C meet our criteria of not more than minimal inflation of type I error rate. We recommend that regulatory agencies accept either. It is our understanding that the FDA has accepted studies with designs like those considered here.
For sponsors, there is a small power advantage to Method C over Method B, so we consider Method C as the method of choice. Another advantage of Method C is that it was designed so that if the study were found to have adequate power at the first stage, the α for that study would be the same as if it were designed to be single-stage study.


❝ For the acceptance of Potvin C see this post.


Terrible.
BTW, FDA recommends Method C (for T/R 0.95) and Method D (for T/R 0.90)… That’s not surprising with Donald Schuirmann as a co-author.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
110 visitors (0 registered, 110 guests [including 20 identified bots]).
Forum time: 04:16 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5